<SEC-DOCUMENT>0001144204-17-050902.txt : 20171002
<SEC-HEADER>0001144204-17-050902.hdr.sgml : 20171002
<ACCEPTANCE-DATETIME>20171002152444
ACCESSION NUMBER:		0001144204-17-050902
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171002
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171002
DATE AS OF CHANGE:		20171002

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TITAN PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000910267
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943171940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13341
		FILM NUMBER:		171114350

	BUSINESS ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6502444990

	MAIL ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v476295_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C.&nbsp; 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of Earliest Event Reported):
October 2, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>Titan
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Delaware</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or other jurisdiction of incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-13341</B></FONT></TD>
    <TD STYLE="width: 50%; padding: 0; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3171940</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number) </FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #3B3B3B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>400 Oyster Point Blvd., Suite 505, South
San Francisco, CA</B> 94080</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%; text-align: center">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><BR>
<B>650-244-4990</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%; text-align: center">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant's telephone number including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%; text-align: center">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant's former name or former address,
if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12(b) under
the Exchange Act (17 CFR 240.14a-12(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 8.01.</B></TD><TD STYLE="text-align: justify"><B>Other Events.</B></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 2, 2017, Titan Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
announced a collaboration with Opiant Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid
relapse and overdose in individuals with opioid use disorder using the Company&rsquo;s proprietary ProNeura&trade; sustained release
technology to administer an opioid antagonist.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the press release issued by the Company is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 9.01.</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit No. </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="v476295_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1&nbsp;</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="v476295_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated October 2, 2017.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">TITAN PHARMACEUTICALS, INC.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 35%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Sunil Bhonsle</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Sunil Bhonsle</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Chief Executive Officer and President</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: October 2, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 283.5pt; text-indent: -283.5pt">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v476295_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 78pt; width: 174.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Titan Pharmaceuticals and Opiant Pharmaceuticals
Collaborate to Explore a New Approach to Opioid Use Disorder Treatment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SOUTH SAN FRANCISCO, Calif. &ndash;
</B>October 2, 2017 <B>&ndash; </B>Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) today
announced a collaboration to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals
with opioid use disorder. The companies will conduct a feasibility assessment of a subcutaneous implant using Titan&rsquo;s proprietary
ProNeura&trade; sustained release technology to administer an opioid antagonist. A product that delivers non-fluctuating, therapeutic
levels of an opioid antagonist, continuously for up to 6 months, may be ideally suited for the prevention of opioid relapse and
overdose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Relapse and fatal overdose among those
with opioid use disorder is significantly higher than any other type of drug addiction. As many as 91 percent of those in recovery
will experience a relapse. At least 59 percent of those who relapse do so within the first week of sobriety, while 80 percent relapse
within a month after discharging from a treatment and detox program.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>i</SUP></FONT>
The risk of a fatal overdose is at its highest during a relapse. Even returning to a low dose of opioids after a period of abstinence
can result in an overdose for a long-term opioid user. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>ii</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Currently, the only FDA-approved
opioid antagonist for relapse prevention is a monthly depot injection of naltrexone,&rdquo; said Opiant CEO Roger Crystal, M.D.
&ldquo;A product with a six-month duration would allow patients to be opioid-free for a longer period, providing a greater window
for long-term recovery, and most critically, relapse and overdose prevention. This six-month duration would mean that patients
only have to make one good decision to initiate therapy, which is important because the longer patients receive pharmacological
treatment, the less likely they are to relapse and possibly overdose.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are pleased to collaborate with
Opiant on this important project to evaluate the addition of an opioid antagonist implant to the armamentarium of products to treat
opioid use disorder,&rdquo; said Titan President and CEO Sunil Bhonsle. &ldquo;Our knowledge from developing the FDA-approved Probuphine&reg;
(buprenorphine) implant for the maintenance treatment of opioid addiction, coupled with the drug development expertise at both
companies, should enable us to complete this evaluation relatively rapidly and, hopefully, with a successful result.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Titan continues to explore opportunities
to expand the use of its ProNeura long-term, continuous drug delivery platform, and recently commenced a Phase 1/2 clinical study
of a ropinirole implant for treating Parkinson&rsquo;s disease. An implantable triiodothyronine (T3) product for the treatment
of hypothyroidism is completing non-clinical development focused on formulation optimization. Titan is also collaborating with
the Walter Reed Army Institute of Research and the Southwest Research Institute in the early non-clinical evaluation of the implant
drug delivery platform in malaria prophylaxis. Additional ProNeura feasibility evaluations are ongoing in the area of chronic pain
treatment with a peripherally acting Kappa opioid receptor agonist, and in the treatment of type 2 diabetes with currently approved
peptides.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>i </SUP></FONT>Smyth,
B. P., Barry, J., Keenan, E. &amp; Ducray, K. (2010).&nbsp;<B>Lapse and relapse following inpatient treatment of opiate
dependence</B>.&nbsp;<I>Irish Medical Journal</I>.&nbsp;<I>103(6),176&ndash;179.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>ii</SUP></FONT>
<I>http://www.alcoholismdrugabuseweekly.com/m-article-detail/even-a-low-dose-of-opioids-after-a-short-period-of-abstinence-can-result-in-overdose.aspx</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Opiant is committed to innovation and product
development in the addiction space. The company is developing additional therapies for opioid use disorder, including advancing
the pre-clinical development of its heroin vaccine candidate, which was licensed in October 2016 from the Walter Reed Army Institute
of Research and the National Institute on Drug Abuse (NIDA). The company&rsquo;s pipeline of nasal opioid antagonists also addresses
both alcohol use and eating disorders. Opiant continues to maintain an active presence in national organizations such as the National
Institutes of Health (NIH), and Dr. Crystal was recently invited to testify before the President's Commission on Combating Drug
Addiction and the Opioid Crisis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Titan Pharmaceuticals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Titan Pharmaceuticals Inc. (NASDAQ:TTNP),
based in South San Francisco, CA, is developing proprietary therapeutics primarily for the treatment of serious medical disorders.
The company's lead product is Probuphine&reg;, a novel and long-acting formulation of buprenorphine and the first and only commercialized
treatment of opioid dependence approved by the U.S. Food and Drug Administration to provide continuous, around-the-clock blood
levels of buprenorphine for six months following a single procedure. Probuphine employs Titan's proprietary drug delivery system
ProNeura&trade;, which is capable of delivering sustained, consistent levels of medication for three months or longer. Titan has
granted commercial rights in the U.S. and Canada for Probuphine to Braeburn Pharmaceuticals. The ProNeura technology has the potential
to be used in developing products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining
consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information
about Titan, please visit <FONT STYLE="color: blue"><U>www.titanpharm.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Opiant Pharmaceuticals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Opiant Pharmaceuticals, Inc. is a specialty
pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders
as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid
antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN&reg;
Nasal Spray, is approved for marketing in the U.S. and Canada by the company&rsquo;s partner, Adapt Pharma Operations Limited.
For more information please visit: www.opiant.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #363636"><I>This press release may contain &quot;forward-looking
statements&quot; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other
statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's
current expectations include those risks and uncertainties relating to the commercialization of Probuphine, the regulatory approval
process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and
strategic agreements and relationships.&nbsp; We expressly disclaim any obligation or undertaking to release publicly any updates
or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CONTACT INFORMATION:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Titan Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sunil Bhonsle, President &amp; CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(650) 244-4990</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Susan Thomas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(650) 989-2216</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: blue"><U>sthomas@titanpharm.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stephen Kilmer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(650) 989-2215&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: blue"><U>skilmer@titanpharm.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &]!'L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT?\ "HM _P"?S4_^_L?_ ,11_P *BT#_ )_-3_[^Q_\ Q%'LY!_;N#[O[O\
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M'05N445TI6/@:E256;G-W;"BBB@@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+/C+_ ,P3
M_MO_ .TZ]3KRSXR_\P3_ +;_ /M.HG\)Z>3_ .^P^?Y,\KHHHKG/N0HHHH *
M*** "BBB@ HHHH **** "O:/A%_R*=U_U_/_ .@1UXO7M'PB_P"13NO^OY__
M $".M*?Q'D9[_N;]5^IW]%%%;GQ04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!Q?Q2_P"1*D_Z[Q_SKPRO<_BE_P B5)_UWC_G7AE85-S[
M+(?]T^;_ $"BBK^C:1<ZYJL&GVBYDE;ECT1>['V J#V924(N4G9(Z+X?^$SX
MBU7[3=(3IUJP,F1Q(W9/ZGV^M>[    # '050T;2;70]*@T^T7$42XR>K'NQ
M]S5^NB,>5'P>8XUXNMS?96W]>844451P!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>6?&7_F"?]M__:=>IUY9\9?^8)_VW_\ :=1/X3T\G_WV'S_)GE=%%%<Y]R%%
M%% !1110 4444 %%%% !1110 5[1\(O^13NO^OY__0(Z\7KVCX1?\BG=?]?S
M_P#H$=:4_B/(SW_<WZK]3OZ***W/B@HHIDLL<,9DED6-!U9S@#\: W'T55_M
M/3_^?ZV_[^K_ (T?VGI__/\ 6W_?U?\ &@KDEV?W,M455_M/3_\ G^MO^_J_
MXT?VGI__ #_6W_?U?\: Y)=G]S+5%5?[3T__ )_K;_OZO^-']IZ?_P _UM_W
M]7_&@.279_<RU157^T]/_P"?ZV_[^K_C1_:>G_\ /];?]_5_QH#DEV?W,M45
M5_M/3_\ G^MO^_J_XT?VGI__ #_6W_?U?\: Y)=G]S+5%5?[3T__ )_K;_OZ
MO^-']IZ?_P _UM_W]7_&@.279_<RU157^T]/_P"?ZV_[^K_C1_:>G_\ /];?
M]_5_QH#DEV?W,M455_M/3_\ G^MO^_J_XT?VGI__ #_6W_?U?\: Y)=G]S.5
M^*7_ ")4G_7>/^=>&5[9\3;VTG\'2)#=0R/YT9VI(">OM7B=85-S['(DUA=>
M[_0 "2 !DGH!7N_P_P#"?_".Z3]HND U&Z ,F>L:]D_J??Z5Q_PQ\)?;;D:[
M>Q_Z/"W^C*P^^X_B^@_G]*]@JJ<>K.#.\PYG]6IO1;_Y?YA1116I\V%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %5;S3;#40@OK*VN@F=@GB5]N>N,CBK5% U
M)Q=T[&5_PC&@?] /3/\ P$C_ ,*/^$8T#_H!Z9_X"1_X5JT4K(T]O5_F?WO_
M #,K_A&- _Z >F?^ D?^%'_",:!_T ],_P# 2/\ PK5HHL@]O5_F?WO_ #,K
M_A&- _Z >F?^ D?^%'_",:!_T ],_P# 2/\ PK5HHL@]O5_F?WO_ #,K_A&-
M _Z >F?^ D?^%'_",:!_T ],_P# 2/\ PK5HHL@]O5_F?WO_ #,K_A&- _Z
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M44 %%%% !5#6=7MM#TV2_NQ(84(!\L9/)P*OUR?Q'_Y$J[_WX_\ T,4 5O\
MA:/A_P#N7O\ WZ'_ ,51_P +1\/_ -R]_P"_0_\ BJ\9HIB/9O\ A:/A_P#N
M7O\ WZ'_ ,51_P +1\/_ -R]_P"_0_\ BJ\9HH ]F_X6CX?_ +E[_P!^A_\
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M%% !1110 5SFN>-=*\/WXLKU;@RE!)^[0$8)/N/2NCKQGXH_\C:G_7JG\VH
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M-!_SPC_[X%2T4AD7V:#_ )X1_P#? H^S0?\ /"/_ +X%2T4 1?9H/^>$?_?
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M%,1]&T444AA1110 4444 %%%% !1110 4444 %%%% %'6_\ D ZC_P!>LO\
MZ":^<J^C=;_Y .H_]>LO_H)KYRIB/1/A+_R%-1_ZXK_Z%7J]>4?"7_D*:C_U
MQ7_T*O5Z0PHHHH **** "BBB@ HHHH **** "BBB@ K@/BQ_R ;+_KZ_]E:N
M_K@/BQ_R ;+_ *^O_96H \CKWGP)_P B5IG^XW_H;5X-7O/@3_D2M,_W&_\
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M^^W_ * U=Y\0/!W]IP-JVGQ?Z;&O[V-1S,H[_P"\/U'X5P?@3_D==,_WV_\
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MZ^O_ &5J[^N ^+'_ " ;+_KZ_P#96H \CKWGP)_R)6F?[C?^AM7@U>\^!/\
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M^C=$_P"0#IW_ %ZQ?^@BOG*OHW1/^0#IW_7K%_Z"*8B]1112&%%%% !1110
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M'V_B-;NYOS,MM$1&GEL 6?J>QZ#'YUV7_"KO#_\ ?O?^_H_^)IB/(_[2O_\
MG]N?^_K?XT?VE?\ _/[<_P#?UO\ &O7/^%7>'_[][_W]'_Q-'_"KO#_]^]_[
M^C_XF@#R/^TK_P#Y_;G_ +^M_C1_:5__ ,_MS_W];_&O7/\ A5WA_P#OWO\
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>C5\]>&=7.A^(+2^R1&K[90.Z'AOTY_"OH16#*&4@J1D$=#0 M%%% !1110
M4444 %>,_%'_ )&U/^O5/YM7LU>,_%'_ )&U/^O5/YM0!F>!/^1UTS_?;_T!
MJ]YKP;P)_P CKIG^^W_H#5[S0 4444 %%%% !1110 5F:]H=KX@TJ2QNAC/S
M1R <QMV(K3HH ^<=6TJZT74I;&\3;+&>HZ,.S#V-5 [!64,0K=0#P:]V\8>%
MH?$NFX7:E]""8)#W_P!D^Q_3K7AEQ;S6EQ);W$;1S1L5=&&""*8B*OHW1/\
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M@:W/[$TG_H&67_@.G^%3VUE:V886MM# &^\(HPN?KB@">BBB@ HHHH ****
M"O&?BC_R-J?]>J?S:O9JK7&G6-W)YES96\S@8W21*QQZ9(H \/\  G_(ZZ9_
MOM_Z U>\U4BTK3K>598;"UCD7[KI"H(^A JW0 4444 %%%% !1110 4444 %
M<-X^\'?VQ;G4["/_ $^)?G11S,H_]F';UZ>E=S10!\R5]&Z)_P @'3O^O6+_
M -!%*^CZ6[L[Z;9LS')8P*23^57%540*JA548  P * %HHHH **** "BBB@
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MUM(#\N\!EC.?0R%W^@Q72?L^^(97TG4O"=\2EWIDK211OU",V'7'^R^?^^Z
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M^:L^ ^QBNX#9WQFO8J* /#_^&B<#)\&WW_@1_P#84R+]H^&<$Q>$KN3'79=
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MH5%5GPH'  ^2N/\ B7K/B_QKX=2+4/A[?:>MBYN?M?SMY:A3O!RHXQR?]T4
M?28((!!R#T(HK@/@YXG_ .$F^'ED97W7=A_H<^3R=H&T_BI7GUS7?T %?.GP
M64>)_BSK_B:X_>-&LLT9(^ZTKX&/3";A^-?1=?.'P G_ +'\?Z]H-P=DS0LH
M#<$O%)@CZX9C^!H ^CZ*** "BBB@ KR?]H;_ ))K'_V$(O\ T%Z]8KR?]H;_
M ))K'_V$(O\ T%Z *?@SXQ^"M&\%:-IM[J,R75K:1Q2J+61@&"X(R!@UN?\
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M Z^4.9#^6%_X'7J->7^*/AQK'BSXI:7K=_<V/_"/Z?LV6PD<ROM^8Y7;MY?
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MMRS'^\<?U(!Z?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7S%J?\ R%KS_KN__H1KZ=KYBU/_
M )"UY_UW?_T(UE5Z'TG#OQ5/1?FRK1116)]0%>W?#GPE_8FG?VC>1XO[I> P
MYBCZ@?4]3^ KC_AMX2_M>_\ [6O8\V5LW[M6'$L@_H.I_ >M>TUM3CU9\SGF
M8?\ ,-3?K_E_F%%%%:GS(4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7S%J?_(6O/\ KN__ *$:^G:^8M3_ .0M>?\
M7=__ $(UE5Z'TG#OQ5/1?FRK6OX;T"X\1ZS%80953\TLF.(T'4_T'N167%$\
M\R11(7D=@JJHR23P *]_\%>%T\,Z,L;@-?3X>X<>O91[#^>:B$>9GKYGCEA*
M5U\3V_S^1N:?86^F6$%E:1A((5"HO^>_>K-%%=!\*VY.[W"BBB@04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S%J?
M_(6O/^N[_P#H1KZ=KPGPYX6?Q-XONUD4BQ@G9[A_4;CA1[G^6:SJ*]D>_D=6
M%%5:DWHDOU.D^%_A+ 7Q!?1\G(M$8?@7_H/Q/I7J5-CC2*-8XT5$0!551@ #
MH!3JN*LK'E8S%3Q55U)?+R04444SE"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "J>FZ79Z3 \-E"(D>1I7Y)+
M,3DDDU<HH&I-)I/1A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
